454 filings
Page 3 of 23
6-K
jeeg5ok8s 82gt87
22 May 23
Report of Foreign Private Issuer
5:01pm
CORRESP
oebz3o0g50syl9 uk
18 May 23
Correspondence with SEC
12:00am
F-3/A
bz5us2nrq0rzw4nn z30
17 May 23
Shelf registration (foreign) (amended)
5:20pm
6-K
wedfgu7r4in 1t
16 May 23
Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update
4:01pm
6-K
ynk6jgt9c0j6k
1 May 23
Notice of Annual General Meeting of Shareholders
4:00pm
6-K
o7euf kwg2y9
25 Apr 23
Report of Foreign Private Issuer
8:07am
6-K
m0oo7eox2suswyemk
19 Apr 23
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
8:17am
EFFECT
2y9wib
6 Apr 23
Notice of effectiveness
12:15am
424B3
3unc f794xow
5 Apr 23
Prospectus supplement
5:21pm
424B3
4e8n7i46c3fk yiq
3 Apr 23
Prospectus supplement
8:57am
CORRESP
yoi70esl9o35 fdbyys
3 Apr 23
Correspondence with SEC
12:00am
UPLOAD
2j4q4s81t 09
30 Mar 23
Letter from SEC
12:00am
6-K
81oiq
24 Mar 23
Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron
7:02am
F-3
x400ul5zyh4d l470rk6
23 Mar 23
Shelf registration (foreign)
9:23am
6-K
sbsqtasteams
16 Mar 23
Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study
7:02am
6-K
8rv9e6
14 Feb 23
Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial
7:03am
6-K
0yg6ydc
8 Feb 23
Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results
7:13am
6-K
frop m3ie8mc
3 Feb 23
Report of Foreign Private Issuer
4:10pm
6-K
8uop7 pv26j23nlsz8
2 Feb 23
Report of Foreign Private Issuer
7:01am